Apogee Therapeutics (APGE) Interest & Investment Income (2023 - 2026)

Apogee Therapeutics (APGE) has reported Interest & Investment Income for 4 consecutive years, with $8.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Interest & Investment Income rose 11.48% year-over-year to $8.7 million; the TTM figure through Mar 2026 stood at $23.4 million (down 10.27% YoY), while the FY2025 annual figure was $30.0 million, down 13.56% from the prior year.
• Interest & Investment Income was little changed at $8.7 million in Q1 2026 per APGE's latest filing, from $8.7 million in the prior quarter.
• Across five years, Interest & Investment Income topped out at $9.7 million in Q3 2024 and bottomed at -$506000.0 in Q1 2024.
• Historically, Interest & Investment Income has averaged $4.8 million across 4 years, with a median of $5.9 million in 2023.
• Annual changes were most pronounced in 2024 — Interest & Investment Income slumped 480.45% — and 2025, when it soared 1649.41%.
• Apogee Therapeutics' Interest & Investment Income stood at $5.4 million in 2023, then soared by 60.17% to $8.7 million in 2024, then grew by 0.58% to $8.7 million in 2025, then increased by 0.1% to $8.7 million in 2026.
• Business Quant data shows APGE's Interest & Investment Income at $8.7 million in Q1 2026, $8.7 million in Q4 2025, and $6.3 million in Q3 2025.